背景:越来越多的证据表明,lncRNAABHD11-AS1在肿瘤发生中起着至关重要的作用,并有望成为新的预测生物标志物和癌症治疗的理想靶点。而他们的一些发现由于个别研究的样本量相对较小而相互矛盾。因此,本荟萃分析旨在定量确定ABHD11-AS1与多种人类恶性肿瘤的相关性.
方法:2024年1月1日对8个数据库进行了相关文章的综合筛选。ABHD11-AS1在恶性肿瘤中的意义通过比值比(ORs)或风险比(HRs)和相应的95%置信区间(CI)确定。应用亚组分析和敏感性分析来验证合并结果的可靠性和稳健性。同时,GEPIA2021和UCSCXena数据库被应用于进一步加强结果。
结果:本荟萃分析纳入了14项临床研究,包括8种恶性肿瘤和1215例恶性肿瘤病例。合并结果显示ABHD11-AS1表达增加与淋巴结转移显著相关(OR=2.73,95CI[1.97,3.77],I2=0%,p<0.00001),晚期肿瘤分期(OR=3.14,95CI[2.34,4.21],I2=39%,p<0.00001),和不利的总生存期(OS)(HR=1.81,95CI[1.58,2.06],I2=0%,p<0.00001)。亚组分析和敏感性分析表明,合并结果可靠且稳健。此外,根据GEPIA2021数据库的验证,ABHD11-AS1在8种恶性肿瘤中显著升高。同时,UCSCXena数据库进一步显示ABHD11-AS1表达升高与无进展间期(PFI)评估的不良预后显著相关,无病间隔(DFI),疾病特异性生存率(DSS),和OS。
结论:目前的证据支持ABHD11-AS1表达升高与不良预后相关。因此,ABHD11-AS1可能被认为是筛查癌症和预测恶性肿瘤预后的有前途的生物标志物。此外,有必要采用不同国家的统一研究方案进行更大规模的多中心研究,以进一步验证结论.
BACKGROUND: Accumulating evidence has highlighted that lncRNA ABHD11-AS1 plays an essential role in tumorigenesis and is expected to become a new predictive biomarker and ideal target for cancer therapy, whereas some of their findings are conflicting due to the relatively small sample size of individual studies. Thus, this meta-analysis aimed to quantitatively ascertain the association of ABHD11-AS1 with diverse human malignancies.
METHODS: Eight databases were comprehensively screened for relevant articles on January 1, 2024. The significance of ABHD11-AS1 in malignancies was determined by odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence interval (CI). Subgroup analyses and sensitivity analyses were applied to verify the reliability and robustness of the pooled results. Simultaneously, the GEPIA2021 and UCSC Xena databases were applied to further strengthen the results.
RESULTS: Fourteen clinical studies comprising eight kinds of malignancies and 1215
malignancy cases were enrolled into this meta-analysis. The pooled results showed that increased ABHD11-AS1 expression was remarkably associated with lymph node metastasis (OR = 2.73, 95%CI [1.97, 3.77], I2 = 0%, p < 0.00001), advanced tumor stage ( OR = 3.14, 95%CI [2.34, 4.21], I2 = 39%, p < 0.00001), and unfavorable overall survival (OS) (HR = 1.81, 95%CI [1.58, 2.06], I2 = 0%, p < 0.00001). Subgroup analyses and sensitivity analyses indicated that the pooled results were reliable and robust. Additionally, ABHD11-AS1 was significantly increased in eight kinds of malignancies according to the validation of the GEPIA2021 database. Meanwhile, the UCSC Xena databases further revealed that elevated ABHD11-AS1 expression was significantly associated with poor prognosis as assessed by progression free interval (PFI), disease free interval (DFI), disease specific survival (DSS), and OS.
CONCLUSIONS: Current evidence supports the association of elevated ABHD11-AS1 expression with poor prognosis. Thereby, ABHD11-AS1 may be considered as a promising biomarker to screen cancer and predict
malignancy prognosis. Also, there is a necessity for larger-scale multicenter studies with uniform study protocols from different countries to further validate the conclusions.